| Literature DB >> 27682438 |
Ayukenchengamba Bate1, Helen K Kimbi2,3, Emmaculate Lum2,4, Leopold G Lehman5, Elias F Onyoh6,7, Lucy M Ndip8, Conica M Njabi2, Calvin Tonga5, Godlove B Wempnje2, Roland N Ndip8,9, Pascal O Bessong10.
Abstract
BACKGROUND: Malaria is one of the leading causes of morbidity and mortality in children and HIV infection as well as other factors may worsen the situation. This study was aimed at determining the factors influencing malaria parasite prevalence and density as well as anaemia in HIV-infected children in Mutengene, Cameroon from November, 2012 to April, 2013.Entities:
Keywords: Anaemia; Cameroon; HIV-infected children; Malaria parasite prevalence and density
Year: 2016 PMID: 27682438 PMCID: PMC5041210 DOI: 10.1186/s12879-016-1853-z
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Factors influencing malaria parasite prevalence and density in a paediatric HIV infected population in Cameroon
| Characteristic/category | Number examined | Number positive (%) | Bivariate analysis | Multivariate analysis | GMPD (range) | Statistic |
| ||
|---|---|---|---|---|---|---|---|---|---|
| OR (95 % CI) |
| OR (95 % CI) |
| ||||||
| Age Group (years) | |||||||||
| < 5 | 66 | 16 (24.2) | 1.67 (0.62–4.12) | 0.455 | 1.02 (0.28–3.71) | 0.976 | 633.0 (80–24000) | H = 3.406 | 0.18 |
| 5–10 | 120 | 34 (28.3) | 1.97 (0.84–4.67) | 0.167 | 3.05 (1.11–8,42) | 0.031* | 234.0 (40–24000) | ||
| 11–15 | 48 | 8 (16.7) | Reference | 463.3 (40–16000) | |||||
| Sex | |||||||||
| Males | 96 | 14 (14.6) | Reference | 549.0 (40–2400) | U = 218.0 | 0.10 | |||
| Females | 138 | 44 (31.9) | 2.74 (1.40–5.36) | 0.004* | 3.08 (1.37–6.93) | 0.007* | 290.0 (40–24000) | ||
| Fever | |||||||||
| Yes | 14 | 4 (28.6) | 1.23 (0.37–4.08) | 0.985 | 1.38 (0.24–7.88) | 0.716 | 3098.4 (400–24000) | U = 34.00 | 0.02* |
| No | 220 | 54 (24.5) | Reference | 287.3 (40–2400) | |||||
| CD4 T cell (cells/μl of blood) | |||||||||
| < 200 | 28 | 8 (28.6) | 1.20 (0.49–2.96) | 0.873 | 1.80 (0.55–5.85) | 0.33 | 82.4 (40–360) | H = 11.598 | 0.003* |
| 200–499 | 44 | 12 (27.3) | 1.07 (0.37–3.06) | 0.881 | 1.20 (0.46–3.13) | 0.70 | 405.2 (80–16000) | ||
| ≥ 500 | 144 | 36 (25.0) | Reference | 491.3 (40–24000) | |||||
| Clinical stages | |||||||||
| Stage 1 | 44 | 16 (36.4) | 4.29 (1.28–14.4) | 0,027* | 10.38 (2.43–44.46) | 0.0016* | 191.2 (40–5040) | H = 14.36 | 0.002* |
| Stage 2 | 62 | 10 (16.1) | 1.44 (0.42–5.00) | 0.782 | 1.46 (0.36–5.87) | 0.59 | 512.2 (40–5400) | ||
| Stage 3 | 82 | 24 (29.3) | 3.10 (0.99–9.77) | 0.077 | 2.62 (0.76–9.09) | 0.13 | 498.4 (80–2400) | ||
| Stage 4 | 34 | 4 (11.8) | Reference | 40.0 (40–40) | |||||
| Use of ART | |||||||||
| Yes | 182 | 52 (28.6) | Reference | 314.8 (40–24000) | U = 136.00 | 0.62 | |||
| No | 52 | 6 (11.5) | 3.07 (1.24–7.61) | 0.019* | 0.194 (0.06–0.62) | 0.0001* | 635.0 (40–16000) | ||
OR Odds Ratio, *Statistically significant, CI Confidence Interval, $:Estimated by Yates adjusted Chi-Square, £:Estimated by Multiple Logistic Regression
Fig. 1Malaria parasite prevalence in the different prevention grades
Malaria parasite prevalence and density with respect to status of anaemia and severity in the study population
| Characteristic/category | Number examined | Number positive for malaria (%) | OR (CI) | GMPD (range) |
|---|---|---|---|---|
| Anaemic status | ||||
| Non anaemic | 118 | 28 (23.7) | Reference | 164.5 (40–960) |
| Anaemic | 116 | 30 (25.9) | 1.12 (0.62–2.03) | 663.6 (40–24000) |
| Level of significance |
| U = 288.0, | ||
| Anaemia severity | ||||
| Mild | 40 | 14 (35.0) | Reference | 232.9 (40–5040) |
| Moderate | 66 | 16 (24.2) | 0.59 (0.25–1.40) | 1658.8 (40–24000) |
| Severe | 10 | 0 (0.0) | --- | 0 |
| Level of significance |
| U = 58.0, | ||
*Statistically significant, CI Confidence Interval, −-- Statistic that could not be computed
Factors influencing the prevalence of anaemia in the study population
| Characteristic/category | Number examined | Number anaemic (%) | Bivariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| OR (95 % CI) |
| OR (95 % CI) |
| |||
| Age group (years) | ||||||
| < 5 | 66 | 22 (33.3) | 0.36 (0.17–0.77) | 0.014* | 0.68 (0.25–1.87) | 0.45 |
| 5–10 | 120 | 66 (55.0) | 0.87 (0.44–1.72) | 0.825 | 0.74 (0.34–1.62) | 0.45 |
| 11–15 | 48 | 28 (58.3) | Reference | |||
| Sex | ||||||
| Female | 138 | 74 (53.6) | 1.49 (0.88–2.51) | 0.176 | 2.15 (1.11–4.15) | 0.024* |
| Male | 96 | 42 (43.7) | Reference | |||
| Presence of fever | ||||||
| No | 220 | 104 (47.3) | Reference | |||
| Yes | 14 | 12 (85.7) | 6.69 (1.46–30.60) | 0.012* | 3.65 (0.69–19.20) | 0.13 |
| CD4 T Cell category (cells/μl) | ||||||
| < 200 | 28 | 16 (57.1) | 2.10 (0.92–4.76) | 0.114 | 1.99 (0.76–5.18) | 0.16 |
| 200–499 | 44 | 32 (72.7) | 4.19 (1.99–8.81) | 0.00017* | 3.79 (1.68–8.52) | 0.0013* |
| ≥ 500 | 144 | 56 (38.9) | Reference | |||
| Clinical stages | ||||||
| Stage 1 | 44 | 18 (40.9) | 0.48 (0.12–1.20) | 0.180 | 0.73 (0.24–2.17) | 0.57 |
| Stage 2 | 62 | 34 (54.8) | 0.85 (0.36–1.98) | 0.87 | 0.97 (0.35–2.64) | 0.95 |
| Stage 3 | 82 | 36 (43.9) | 0.55 (0.24–1.23) | 0.21 | 0.45 (0.18–1.15) | 0.09 |
| Stage 4 | 34 | 20 (58.8) | Reference | |||
| Use of ART | ||||||
| No | 52 | 30 (57.7) | 1.52 (0.82–2.84) | 0.242 | 1.29 (0.60–1.29) | 0.51 |
| Yes | 182 | 86 (47.3) | Reference | |||
OR Odds Ratio, CI Confidence Interval, $: Estimated by Yates adjusted Chi-Square, £: Estimated by Multiple Logistic Regression. *Statistically significant